Inventory of real-world data sources in Japan: Annual survey conducted by the Japanese Society for Pharmacoepidemiology Task Force

被引:11
作者
Kumamaru, Hiraku [1 ,2 ]
Togo, Kanae [1 ,3 ]
Kimura, Tomomi [1 ,4 ]
Koide, Daisuke [1 ,5 ]
Iihara, Naomi [1 ,6 ]
Tokumasu, Hironobu [1 ,7 ]
Imai, Shinobu [1 ,8 ]
机构
[1] Japanese Soc Pharmacoepidemiol, Database Task Force, Tokyo, Japan
[2] Univ Tokyo, Dept Healthcare Qual Assessment, Grad Sch Med, 7-3-1 Hongo,Bunkyo Ku, Tokyo, Japan
[3] Pfizer Japan Inc, Hlth & Value, Tokyo, Japan
[4] Astellas Pharma US Inc, Real World Data Sci, Data Sci, Northbrook, IL USA
[5] Univ Tokyo, Grad Sch Med, Dept Biostat & Bioinformat, Tokyo, Japan
[6] Tokushima Bunri Univ, Kagawa Sch Pharmaceut Sci, Sanuki City, Japan
[7] Kurashiki Cent Hosp, Clin Res Ctr, Kurashiki, Okayama, Japan
[8] Showa Univ, Sch Pharm, Dept Healthcare & Regulatory Sci, Div Pharmacoepidemiol, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo, Japan
关键词
administrative claims data; database; pharmacoepidemiology; survey; DATABASES;
D O I
10.1002/pds.5680
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: The Database Task Force of the Japan Society for Pharmacoepidemiology began its annual surveys of databases available for clinico and pharmacoepidemiological studies in 2010. In this report, we summarize the characteristics of the databases available in Japan based on the results of our 2021 survey to illustrate the recent developments in the infrastructure for database research in Japan. Methods: We included 20 major databases from the academia, government, or industry that were accessible to third parties. We used a web-based questionnaire to ask the database providers about their characteristics, such as their organization, data source(s), numbers of individuals enrolled, age distribution, code(s) used, and average follow-up periods. Results: We received responses from all 20 databases approached: eight hospital-based databases, six insurer-based databases, four pharmacy-based databases, and two in the "other" category. Among them, 17 contained information from medical claims, pharmacy claims, and/or Diagnosis Procedure Combination data. Most insurer databases contained health check-up data that could be attached to the claims component. Some hospital-based databases had data from electronic medical records. Most insurer-based databases collected data from the insurers of working-age employees and therefore had limited coverage of older people. Most databases coded their medication data using the Japanese reimbursement codes, and many provided Anatomical Therapeutic Chemical Classification codes. Conclusions: The number of databases available for clinico and pharmacoepidemiological research and the proportion of the population they cover are increasing in Japan. The differences in their characteristics mean that the appropriate database must be selected for a particular study purpose.
引用
收藏
页数:9
相关论文
共 36 条
  • [31] Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan
    Yamaguchi, Mitsune
    Inomata, Satomi
    Harada, Sayoko
    Matsuzaki, Yu
    Kawaguchi, Maiko
    Ujibe, Mayuko
    Kishiba, Mari
    Fujimura, Yoshiaki
    Kimura, Michio
    Murata, Koichiro
    Nakashima, Naoki
    Nakayama, Masaharu
    Ohe, Kazuhiko
    Orii, Takao
    Sueoka, Eizaburo
    Suzuki, Takahiro
    Yokoi, Hideto
    Takahashi, Fumitaka
    Uyama, Yoshiaki
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (10) : 1395 - 1404
  • [32] Yamamoto Ryuichi, 2016, Japan Med Assoc J, V59, P91
  • [33] Validity of diagnoses, procedures, and laboratory data in Japanese administrative data
    Yamana, Hayato
    Moriwaki, Mutsuko
    Horiguchi, Hiromasa
    Kodan, Mariko
    Fushimi, Kiyohide
    Yasunaga, Hideo
    [J]. JOURNAL OF EPIDEMIOLOGY, 2017, 27 (10) : 476 - 482
  • [34] Yasunaga H., 2019, Ann Clin Epidemiol, V1, P76, DOI [DOI 10.37737/ACE.1.376, 10.37737/ace.1.376, DOI 10.37737/ACE.1.3_76]
  • [35] Yasunaga H., 2019, ACE, V1, P28, DOI [10.37737/ace.1.228, DOI 10.37737/ACE.1.228]
  • [36] Yoshihara H., 2022, Japanese J Pharmacoepidemiol, V27, P3, DOI DOI 10.3820/JJPE.27.3